Table 3 |
||
|
Incremental cost-effectiveness of artemether-lumefantrine including second line treatment |
||
| AL |
SP |
|
|
|
||
| 1. Total patients |
55,509 |
55,509 |
| 2. First wave first-line, US$a |
407,436.06 |
343,600.71 |
| 3. Second wave first-line, US$b |
58,263.36 |
143,968.70 |
| 4. Second line treatment, US$c |
6,088.60 |
182,575.57 |
| 5. Incremental cost, US$ |
-176,486.97 |
- |
| 6. ACER including second line treatment, US$ |
9.92 |
20.78 |
| 7. ICER including second line treatment, US$ |
-11.52 |
- |
|
|
||
|
(a) All patients receive first wave first-line (b) 14.7% of AL and 41.9% of SP recipients fail first-line and receive repeated dosage (c) cost of second line treatment is us$16.32 |
||
|
Chanda et al. Malaria Journal 2007 6:21 doi:10.1186/1475-2875-6-21 |
||
